NEW YORK (Reuters Health) – Most therapies now available for fibromyalgia are not backed by high-quality evidence for their effectiveness in reducing pain or improving quality of life (QOL), according to a new research review.
“Out of 65 different therapies included in our review, we only found high-quality evidence supporting the effectiveness of cognitive-behavioral therapies, antidepressants and central nervous system depressants,” Dr. Vinicius Cunha Oliveira of the Universidade Federal dos Vales do Jequitinhonha e Mucuri in Diamantina, Brazil, told Reuters Health by email.
“Although the certainty about the effectiveness of these therapies is high, their effect sizes may not be clinically meaningful to patients,” he added. “It should be considered by clinicians in the decision-making process and discussed with their patients.”
Advertisement:
No products found.
I get commissions for purchases made through links on this website. As an Amazon Associate I earn from qualifying purchases.
